FDA seeks more time to review Takeda's Actos-alogliptin combo

07/23/2009 | Bloomberg

Takeda Pharmaceutical said the FDA moved to Sept. 4 its deadline to decide whether to approve a drug that blends diabetes drugs Actos and alogliptin. Review of the fixed-dose combination is separate from Takeda's application for alogliptin, which failed to gain FDA approval last month.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations